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Abstract
Background: While hypertension still is a major health problem worldwide, some studies have indicated that the
blood pressure level has decreased in some populations. This population based cohort study aims at analysing
blood pressure changes in a large Norwegian population over a 22 year period.
Methods: Data is acquired from three comprehensive health surveys of the HUNT Study conducted from 1984–86
to 2006–08. All citizens of Nord-Trøndelag County, Norway, >20 years were invited: 74,549 individuals participated
in 1984–86; 64,523 in 1995–97; and 43,905 in 2006–08.
Results: Both systolic and diastolic blood pressure levels decreased substantially from mid 1980s to mid 2000s,
with the most pronounced decrease from 1995–97 to 2006–08 (from 136.0/78.9 to 128.3/70.9 mmHg in women
and from 140.1/82.1 to 133.7/76.5 mmHg in men). Although the use of blood pressure lowering medication
increased, there was a considerable decrease even in those who reported never use of medication (mean decrease
6.8/7.2 mmHg in women and 6.3/5.3 mmHg in men), and the decrease was most pronounced in the elderly
(mean decrease 16.1/12.4 mmHg in women and 14.7/10.4 mmHg in men aged 80+). Mean heart rate, total
cholesterol and daily smoking decreased, self-reported hard physical activity increased, while body weight and
the prevalence of diabetes increased during the same period.
Conclusions: The BP decrease might seem paradoxically, as body weight and prevalence of diabetes increased
during the same period. Salt consumption might have decreased, but no salt data is available. The parallel decrease
in mean heart rate might indicate reduction in the white-coat phenomenon, or increased use of beta blockers or
calcium channel blockers for other diagnosis than hypertension. Additionally, the data could support the “healthy
obese” hypothesis, i.e., that subgroups in the population can sustain obesity without serious health consequences.
Background
A large number of studies have shown the health benefits
of lowering of blood pressure (BP) and the efficacy of spe-
cific lifestyle and pharmacological interventions, but
hypertension is still a major health problem world-wide.
In a study covering 5.4 million participants, mean systolic
blood pressure (SBP) decreased by only 1 mmHg per dec-
ade for men and women between 1980 and 2008, and in
some countries SBP had increased [1]. Western Europe
and Australasia showed a more favorable trend; SBP
decreased by 3.5 mmHg or more per decade in women
and more than 2.0 mmHg per decade in men. In the
WHO MONICA study, following 38 European popula-
tions from mid 1980s to mid 1990s, SBP decreased
2.2 mmHg in men and 3.3 mmHg in women, and diastolic
blood pressure (DBP) decreased 1.4 mmHg in men and
2.2 mmHg in women [2]. However, despite that antihyper-
tensive medication increased, no effect from improving
treatment of hypertension was detected, and other deter-
minants of the BP decrease was therefore suggested to
have had impact in the populations. Except the well-
known effect of drug treatment, little has been achieved in
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understanding the determinants of BP trends on a popula-
tion level [3].
The aim of the present study was therefore to improve
the understanding of the population BP changes. We
systematically assessed both SBP and DBP changes in a
large population over a 22 year period. Having collected
a number of health- and other background data, we have
analyzed the nature of the BP changes in all age groups
20 years and over, special emphasizing on people who
have never taken BP medication.
Methods
We included individuals from the Nord-Trøndelag Health
Study (HUNT), a population-based health study with
medical histories on approximately 120,000 individuals
from Nord-Trøndelag County, Norway, collected in three
surveys (HUNT1, 2, and 3) [4–6]. All residents of the
county aged 20 years and older were invited to participate.
Self-reported questionnaires, clinical examination and
non-fasting venous blood samples (HUNT2 and HUNT3)
were collected in 1984–86 (HUNT1, N = 74,549, 88 % of
invited), 1995–97 (HUNT2, N = 64,523, 71 % of invited)
and 2006–08 (HUNT3, N = 43,905, 59 % of invited)
(Table 1). Totally, 27,605 individuals participated in all
three surveys. The population of Nord-Trøndelag County
(n ~ 130,000) is stable and homogenous, and is representa-
tive of the Norwegian population regarding demography,
socioeconomic factors, morbidity and mortality [5]. After
the HUNT3 survey a comprehensive non-participation
study was conducted, analysing the impact of the decreas-
ing participation rate [7].
Questionnaires
Each participant completed two extensive questionnaires.
First, they received a questionnaire by mail prior to attend-
ing the clinical exam regarding health and life style factors,
including blood pressure treatment, information of cardio-
vascular related diseases and diabetes, physical exercise and
smoking. At attendance, they were handed a second ques-
tionnaire to be completed at home and returned by mail
mainly regarding self-reported diseases [6]. For this study,
we use the following questions (answering alternatives in
parenthesis): Are you taking medication for high blood pres-
sure? (Currently taking medication/Previously, but not
now/Have never taken it). Have you had or do you have:
Myocardial infarction (heart attack)? (Yes/No), Diabetes?
(Yes/No). Do you smoke?(Yes/No). Daily cigarette smoker?
(Yes/No). How much of your leisure time have you been
physically active during the last year? (Hours per week:
None/Less than 1/1-2/3 or more). Vigorous physical activity
(sweating/out of breath)? (Yes/No). What is your highest
level of education? (Primary school 7–10 years, continu-
ation school, folk high school/High school, intermediate
school, vocational school, 1–2 years high school/University
qualifying examination, junior college, A levels/University
or other post-secondary education, less than 4 years/Uni-
versity/College, 4 years or more).
Measurements
In HUNT1 [4], SBP and DBP was measured manually by
specially trained nurses using calibrated mercury manom-
eters. The BP was measured on the right arm with cuffs
adjusted according to the arm circumference, and after
the participant had been sitting relaxed for five minutes.
SBP was recorded at the first Korotkoff sound and the
DBP was recorded when the fifth Korotkoff sound disap-
peared (last sound). SBP and DBP were read twice with
one minute interval. Heart rate was counted manually for
15 s and multiplied by four. In HUNT2 [5], the examin-
ation procedures were similar as in HUNT1, except that
automated measures based on oscillometry was used
(Critikon Dinamap 845XT and XL9301, acquired by GE
Medical Systems Information Technologies in 2000). SBP
and DBP and heart rate were read three times with a one
minute interval. In HUNT3 [6], the same protocol and
procedures as in HUNT2 were used, including Dinamap
devices (XL9301 and Critikon 8100). For practical pur-
poses only two BP and heart rate readings were performed
in a sample of HUNT3 participants (n = 6,188), and they
Table 1 Clinical characteristics of participants in the three
surveys of The HUNT Study, Norway: HUNT1 (1984–86), HUNT2
(1995–997) and HUNT3 (2006–08)
HUNT1 HUNT2 HUNT3
(1984–86) (1995–97) (2006–08)
Participants (n) 74,549 64,523 43,905
Age, years (mean, SD) 49.1 (18.0) 50.4 (17.4) 53.1 (16.1)
Female (%) 50.7 53.2 54.6
Systolic BP, mmHg (mean, SD) 136.8 (23.3) 137.9 (21.8) 130.7 (18.6)
Diastolic BP, mmHg (mean, SD) 84.0 (11.7) 80.3 (12.2) 73.4 (11.2)
BP medication now/previosly (%) 13.0 13.7 20.9
BMI, kg/m2 (mean, SD) 25.2 (3.9) 26.4 (3.9) 27.2 (4.4)
Heart rate, beats/min (mean, SD) 74.9 (12.6) 73.2 (12.7) 70.2 (11.5)
Myocardial infarction (%) 2.6 3.3 3.2
Stroke (%) 1.8 1.9 2.6
Diabetes (%) 2.9 3.1 4.4
Se-Total chol, mmol/L (mean, SD) 5.89 (1.26) 5.49 (1.11)
Se-HDL chol, mmol/L (mean, SD) 1.38 (0.39) 1.35 (0.35)
Se-Triglycerides,mmol/L
(mean, SD)







Se-Glucose, mmol/L (mean, SD) 5.47 (1.54) 5.59 (1.57)
Waist circumference, cm
(mean, SD)
86.5 (11.8) 93.6 (12.3)
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were excluded from the analyses [6]. BP measured with
the Dinamap devices used in HUNT2 and 3 are slightly
lower than those measured with a sphygmomanometer,
especially for DBP [8]. Height and weight were measured
using standardized instruments with the participants wear-
ing light clothes without shoes; height to the nearest 1.0 cm
and weight to the nearest 0.5 kg. Waist circumference was
measured horizontally at the height of the umbilicus to the
nearest 1.0 cm.
Laboratory measurements
For HUNT2 and HUNT3, non-fasting blood samples
were drawn whenever the participants attended the
screening site. In HUNT2 total serum cholesterol was
measured using an enzymatic colorimetric cholinesterase
method, HDL by enzymatic colorimetric cholesterol
esterase method after precipitation with phosphor tung-
sten and magnesium ions, non-fasting triglycerides by
enzymatic hexokinase method, non-fasting serum glu-
cose by an enzymatic hexokinase method and serum
creatinin by Jaffè method [9].
Statistics
All HUNT data are linked to the unique 11-digit per-
sonal identification number given to each Norwegian
citizen at birth, enabling linkage of data for each indi-
vidual. We used the second BP reading in HUNT1,
and the mean of the second and third reading in
HUNT2 and HUNT3. Body Mass Index (BMI) was cal-
culated according to WHO (kg/m2) [10]. Quartiles of total
cholesterol (Q1-4) were calculated for HUNT2
(<4.8 mmol/L, 4.8–5.59 mmol/L, 5.6–6.39 mmol/L, and ≥
6.4 mmol/L, respectively). Quartiles of heart rate (Q1-4)
were calculated for HUNT2 (beats/min): Q1: <64.0, Q2:
64.5–71.9, Q3: 72.0–80.9, Q4: ≥ 81.0. Pack years were
calculated as years of daily smoking times number of
packs smoked per day. Change in BP from HUNT2 to
HUNT3 was calculated as delta BP, i.e., BP (mmHg) in
HUNT2 minus BP (mmHg) in HUNT3. Delta BMI: BMI
(kg/m2) in HUNT2 minus BMI (kg/m2) at HUNT3, delta
Se-cholesterol: total cholesterol (mmol/L) at HUNT2
minus total cholesterol (mmol/L) at HUNT3, delta heart
rate (HR): HR (beats/min) at HUNT2 minus HR (beats/
min) at HUNT3. We performed linear regression analyses
in women and men separately with delta DBP as the de-
pendant variables. P < 0.05 was considered significant.
Nonparametric kernel-density plots were constructed in
Stata (version 13) with the kdensity command and the de-
fault Epanechnikov kernel function was utilized. A kernel-
density plot is a smoothed representation of a histogram
where the area under the curve shows the proportion of
values compared to all values and sums to 1. The other
statistical analyses were performed using the Statistical
Package for the Social Science, version 21.0 (IBM SPSS,
New York).
Results
Valid BP measurements were available on 74,519 indi-
viduals from the mid 1980s (HUNT1), 64,523 individuals
from the mid 1990s (HUNT2) and 43,905 individuals
from mid 2000s (HUNT3). Clinical characteristics of the
study participants are summarized in Table 1.
Blood pressure change in the population
We did not observe change in mean SBP from HUNT1
to HUNT2, while for mean DBP we observed a decrease
of 3.7 mmHg for women and 3.4 mmHg for men (from
82.6 mmHg to 78.9 mmHg and from 85.5 mmHg to
82.1 mmHg, respectively). From HUNT2 to HUNT3
mean SBP decreased by 7.7 mmHg in women and
6.4 mmHg in men (from 136.0 mmHg to 128.3 mmHg
and from 140.1 mmHg to 133.7 mmHg, respectively)
and mean DBP decreased by 8.0 mmHg in women and
5.6 mmHg in men (78.9 mmHg to 70.9 mmHg and
82.1 mmHg to 76.5 mmHg, respectively). Figure 1 illus-
trates that the distributions of SBP in HUNT1 and
HUNT2 were closely overlapping, while SBP in HUNT3
was skewed to the left with the right hand side of the
bell curve somewhat compressed. The distribution of
DBP showed a consistent and parallel shift to the left for
HUNT2 and HUNT3 compared to HUNT1. Stratifying
by age illustrates that both the reduction of SBP and
DBP mean values increased by age in both women and
men, with a maximum decrease in those above 80 years
of age (Fig. 2, Additional file 1: Table S1).
The distribution of BP according to the ESH/ESC defi-
nitions [11] shows a general shift towards the “optimal”
and “normal” categories (<120/80 mmHg and 130-139/
85-89 mmHg, respectively) for both women and men and
in nearly all age groups (Additional file 1: Table S2). The
proportion of participants with “normal” BP according to
the ESH and ESC Guidelines (SBP below 140 mmHg and
DBP below 90 mmHg) [11] increased from 52.8 % in
HUNT1 via 57.4 % in HUNT2 to 71.0 % in HUNT3. The
improved control increased in both sexes and in all age
groups (Fig. 3 and Additional file 1: Table S3).
Blood pressure lowering medication
The prevalence of self-reported BP lowering drug treat-
ment increased from 12.9 % in HUNT1 via 13.7 % in
HUNT2 to 20.6 % in HUNT3, and we observed a decrease
in BP for participants who were currently or had previ-
ously been under treatment between the three measure-
ments. In accordance with the great increase in self-
reported drug treatment from HUNT2 to HUNT3, the
decrease was more pronounced in this period (16.2 mmHg
for SBP and 11.9 mmHg for DBP) compared to the
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change observed from HUNT1 to HUNT2 (1.5 mmHg
for SBP and 4.8 mmHg for DBP) (Table 2). More surpris-
ingly, we observed a similar (although smaller) trend for
those who had never used BP lowering medication: a
decrease of 6.7 mmHg in mean SBP and 6.4 mmHg in
mean DBP between HUNT2 and HUNT3 (Table 2). For
these individuals, the decrease observed in BP between
HUNT2 and HUNT3 was more pronounced among the
older age groups, (Fig. 4 and Additional file 1: Table S4).
Individual trends
We next examined individuals participating in all three
surveys and not reporting use of BP medication (8,947
women and 7,414 men). As expected, in both genders
mean SBP increased from HUNT1 to HUNT2 (8.9 mmHg
in women and 5.8 mmHg in men). The increase from
HUNT2 to HUNT3 was less pronounced, and in one age
group (60–79 years) the observed BP was lower than
11 years previously. Mean DBP was roughly identical in
HUNT1 and HUNT2. However, from HUNT2 to HUNT3
the observed diastolic pressures showed a general decrease
- despite that the participants were 11 years older, and the
decrease was more pronounced in the older age groups in
both sexes (Fig. 5, Additional file 1: Table S5).
Predictors of blood pressure decrease
To follow up on this observation, we further examined
the BP of participants not under current or past treat-
ment. We found several changes in cardiovascular re-
lated risk factors from HUNT2 to HUNT3. Among
these individuals both BMI and non-fasting glucose in-
creased, while total cholesterol, heart rate and self-
reported daily smoking decreased. Also, we observed
a) Systolic blood pressure




























Fig. 1 Nonparametric kernel-density estimates for the distribution of
systolic (a) and diastolic (b) blood pressure in HUNT1 (n = 74,519),
HUNT2 (n = 64,523) and HUNT3 (n = 43,905)
a)
b)
Fig. 2 All participants. Mean systolic (SBP) and diastolic (DBP) blood
pressure in HUNT1 (H1, 38,173 women, 36,376 men), HUNT2
(H2, 34,325 women, 30,198 men) and HUNT3 (H3, 23,968 women,
19,937 men) in women (a) and men (b) by age. (Additional file 1:
Table S1)
Holmen et al. BMC Cardiovascular Disorders  (2016) 16:94 Page 4 of 9
that self-reported hard physical activity increased in the
same period. These changes occurred in both sexes
(Table 3). In bivariate analyses the mean BP decrease
from HUNT2 to HUNT3 was most pronounced in indi-
viduals with the lowest level of education (both SBP and
DBP; Additional file 1: Table S6). Also, the BP decrease
was most pronounced among obese participants (BMI ≥
30 kg/m2; Additional file 1: Table S7) and in those in the
highest quartile of total serum cholesterol (Additional
file 1: Table S8). Parallel to the BP decrease, we also ob-
served a decrease in mean heart rate, from 76.4/73.7
a)
b)
Fig. 3 Per cent of participants with SBP <140 mmHg and DBP
<90 mmHg in HUNT1, HUNT2 and HUNT3 by age in women (a) and
in men (b)
Table 2 Mean systolic (SBP) and diastolic (DBP) blood pressure in individuals taking blood pressure medication “now or previously”
and in individuals “never” taking blood pressure medication
Blood pressure medication n1 SBP mmHg SD Delta SBP mmHg DBP mmHg SD Delta DBP mmHg
HUNT1 «Now or previously» 9,683 158.0 25.1 93.2 11.3
«Never» 65,118 133.7 21.3 82.6 11.2
HUNT2 «Now or previously» 8,860 156.5 23.3 1.5a 88.4 13.1 4.8a
«Never» 55,739 134.9 20.0 −1.2a 79.0 11.6 3.6a
HUNT3 «Now or previously» 9,089 140.3 19.4 16.2b 76.5 11.7 11.9b
«Never» 34,982 128.2 17.5 6.7b 72.6 10.9 6.4b
Differences in blood pressure (Delta SBP and Delta DBP) between HUNT1 and HUNT2 (a) and between HUNT 2 and HUNT 3 (b) by blood pressure medication
1 Number of participants with valid measures varies slightly
a)
b)
Fig. 4 Participants reporting never taking blood pressure
medication. Mean systolic (SBP) and diastolic (DBP) in HUNT1
(H1, 32,114 women, 33,000 men), HUNT2 (H2, 29,178 women, 26,350
men) and HUNT3 (H3, 19,106 women, 15,692 men) by age in
women (a) and in men (b). (Additional file 1: Table S4)
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beats/min in HUNT1 via 75.3/71.0 in HUNT2 to 71.9/
68.3 beats/min in HUNT3 in women/men respectively
(Additional file 1: Table S9).
As a next step we analysed only those individuals who
had participated both in HUNT1, HUNT2 and HUNT3
and reported they had never taken BP medication. While
SBP had not changed substantially from HUNT2 to
HUNT3 in these individuals, despite they were 11 years
older, DBP had decreased substantially (Fig. 5, Additional
file 1: Table S5). We therefore specified linear regression
models with delta DBP (DBP in HUNT2 minus DBP in
HUNT3) as the dependent variable, and found that the
observed DBP decrease from HUNT2 to HUNT3 was
associated with increasing age, decreasing BMI, decreasing
total serum cholesterol and decreasing heart rate. These
associations were consistent in both women and men. In
men there was also an association with myocardial infarc-
tion (Table 4).
Discussion
In this large population based study, mean BP decreased
during the whole period from mid 1980s (HUNT1) to
mid 2000s (HUNT3), but most pronounced from mid
1990s (HUNT2) to mid 2000s (HUNT3). The decrease
was observed both in SBP and DBP, in both genders and
the decrease increased by age. The volume of antihyperten-
sive drug treatment increased in the same period and ex-
plains some of the BP decrease. However, the BP decrease
was significant even in those who reported they had never
taken BP medication. An unexpected finding was the con-
sistent association between blood pressure decrease with
ageing and with decreasing heart rate.
Strengths of our study are the large unselected and
stable population, the large number of health variables
and the consistent methods for clinical measurements
a)
b)
Fig. 5 Individuals participating both in HUNT1 (H1), HUNT2 (H2) and
HUNT3 (H3) and reporting never taking antihypertensive medication.
Mean systolic (SBP) and diastolic (DBP) blood pressure in women (a,
n = 8947) and men (b, n = 7414) by age. (Additional file 1: Table S5)
Table 3 Participants who reported they had never taken blood
pressure medication: Mean Body Mass Index (BMI), total serum
cholesterol, non-fasting serum glucose, and heart rate in HUNT2
and HUNT3 (a), and prevalence (%) of self-reported daily
smoking, hard physical activity and diabetes in HUNT2 and
HUNT3 by gender (b)
Women Men
(a) Mean SD Mean SD
BMI (kg/m2) HUNT21 25.89 4.30 26.22 3.37
HUNT32 26.34 4.62 27.07 3.64
Total cholesterol (mmol/l) HUNT2 5.85 1.32 5.77 1.17
HUNT3 5.34 1.14 5.48 1.06
Non fasting Se glucose (mmol/l) HUNT2 5.27 1.23 5.47 1.50
HUNT3 5.32 1.22 5.59 1.53
Heart rate (beats/min) HUNT2 75.27 12.16 71.06 12.42
HUNT3 71.87 11.03 68.34 11.31
(b) % %





(>3 h/week) HUNT3 20.7 26.1
Self-reported diabetes HUNT2 1.7 2.3
HUNT3 2.1 2.6
1 Number of individuals with valid measures in HUNT2 varied from 28,807 to
29,423 in women and from 26,223 and 26,509 in men, except the question
about physical activity which was answered by 20,112 women and
20,393 men
2 Number of individuals with valid measures HUNT3 varied from 19,254 to
22,065 in women and between 15,814 and 18,114 men, except the question
about physical activity which was answered by 12,511 women and
10,108 men
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and data collection. In HUNT1 BP was measured manu-
ally, while in HUNT2 and HUNT3 it was used auto-
matic devices. The devices were checked and calibrated
by specialists several times during the examination
periods, finding no major errors. The automatic method
was calibrated against manually procedures, showing
slightly lower values, but this could not explain the large
discrepancies in BP levels between the HUNT2 and
HUNT3 surveys [8]. Additionally, in HUNT2 and
HUNT3 the same type of devices and the same protocol
were used, and in all three surveys the measurements
were performed by specially trained nurses, and the rou-
tines were checked repeatedly during the examination
periods. Limits of the present study were the lower par-
ticipation rate in HUNT3 compared to HUNT2 and
HUNT1, especially in the age groups 20–39 and 80+ [6].
The comprehensive non-participation study in HUNT3
demonstrated that proportions of patients with diagnosis
of cardiovascular diseases in general practitioner re-
cords was higher than the prevalence of corresponding
self-reported diseases in HUNT3, but there was close
agreement between the two data sets regarding use of
antihypertensive treatment [7]. As a consequence, we
have no reason to assume that selection bias was a
major factor. Another limitation in the present study
was the lack of information on salt and potassium
consumption.
The increased drug treatment since HUNT2 was an
important aspect when studying blood pressure changes
in this population. We therefore estimated in a model
the potential effect on population BP level from the
increased drug treatment between HUNT2 and HUNT3:
Provided those with BP above the 90 percentile in
HUNT2 had their SBP decreased with 20 mmHg and
DBP decreased with 10 mmHg, this effect on a popula-
tion level could only explain about 2 mmHg decrease in
SBP and 1 mmHg in DBP (data not shown).
The main challenge is to understand the large BP de-
crease from HUNT2 to HUNT3 in individuals reporting
they had never taken BP medication, and especially since
the decrease occurred in a period with large increase in
body weight and diabetes. Recall bias or misinterpret-
ation of the purpose of drugs prescribed might occur,
however, validation of this question gave no indication
of major misclassification [12]. The cardiovascular risk
profile improved during the period, consistent with de-
creased cardiovascular morbidity and mortality in the
population [13, 14]. Data on lipid lowering drugs were
not available, but national statistics demonstrates that
the consumption of these drugs had a large increase
in the period from mid 1990s to mid 2000s [15].
There is, however, no evidence that lipid lowering
drugs may have the effect on BP level demonstrated
in the present study [16, 17].
BP decrease is reported in other industrialized popula-
tions since 1990s, along with increasing body weight [18].
In the WHO MONICA project covering 38 populations in
21 countries from mid 1980s to mid1990s average BP
decreased 2.26 mmHg [2], while a study from England
demonstrated that mean SBP had fallen by 1.6 and
4.3 mmHg in men and women in the period from 1994 to
2003 [19]. In the first study from Norway describing the BP
decrease, including 40–42 year old participants from eight
counties, demonstrated systolic decrease of 6.7 mmHg in
women and 6.1 mmHg in men and diastolic decrease of
5.6 mmHg in women and 5.4 mmHg in men, without find-
ing a reasonable explanation to the decrease [20]. A recent
report from the Tromsø Study, Norway, found that mean
systolic and diastolic pressure decreased from 1979 to 2008
in both genders in the age group 30 to 89 years. The de-
crease in systolic blood pressure in age group 40–49 years
was 10.6 mmHg in women and 4.5 mmHg in men [21].
The larger BP decrease with increasing age in the
present study has, to our knowledge, not been described
Table 4 Participants both in HUNT1, HUNT2 and HUNT3, reporting they had never used antihypertensive medication. Linear
regression models with association between delta DBP (change in DBP from HUNT2 to HUNT3, i.e., DBP in HUNT2 minus DBP in
HUNT3) and relevant confounders: Age, delta BMI (BMI in HUNT2 minus BMI at HUNT3), delta Se-cholesterol (total cholesterol at
HUNT2 minus total cholesterol at HUNT3), delta heart rate (HR) (HR at HUNT2 minus HR at HUNT3), self-reported myocardial
infarction (MI) (at HUNT3), delta smoking (pack years in HUNT2 minus pack years in HUNT3), self-reported diabetes (at HUNT3)
(Yes = 1, No = 0) and education level (Low = 1, High = 5)
Delta DBP
Women1 Men2
Beta p Beta p
Age (years, at HUNT2) .137 <.001 .126 <.001
Delta BMI (kg/m2) .093 <.001 .137 <.001
Delta Se-cholesterol (mmol/l) .107 <.001 .143 <.001
Delta HR (beats/min) .169 <.001 .168 <.001
Self-reported MI (Yes = 1, No = 0) .062 <.001
1Excluded from the model (not significant): Delta smoking, self-reported diabetes, non-fasting glucose, hard physical exercise, education level, self-reported MI
2Excluded from the model (not significant): Delta smoking, self-reported diabetes, non-fasting glucose, hard physical exercise, education level
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previously. The parallel decrease in BP and heart rate
and the association between BP decrease and heart rate
decrease (linear regression) might indicate some kind of
increased parasympathetic activity with strongest effect
in elderly obese individuals. One explanation could be
reduction in the white-coat phenomenon, but we have
no data indicating why this effect should be so strong in
the period from HUNT2 to HUNT3. Increased use of
calcium channel blockers and beta blockers for other
diagnosis than hypertension might explain some of the
heart rate and blood pressure decrease, however, no data
was available. In the period between HUNT2 and
HUNT3 the Norwegian population increased consump-
tion of fruit and vegetables, increasing the potassium (K)
intake [22]. If the change in food habits also has induced
less salt (NaCl) consumption, especially in elderly obese
individuals, this might explain some of the BP decrease
[23]. Considering the increased salt sensitivity in elderly
[24] this might even explain the increasing BP decrease
by age [25, 26]. Another hypothesis might be that sub-
groups in the population can sustain obesity without
serious health consequences, i.e., the “healthy obese”
hypothesis [27]. In another study of the same popula-
tion, obesity without metabolic abnormalities did not
confer substantial excess risk for myocardial infarction,
a major cause of death [28]. Both the use of medication
(other than for hypertension), the hypothesis about in-
creased parasympathetic activity, the hypothesis about
decreased salt consumption in elderly and the “healthy
obese” hypothesis, should be explored in future studies.
Conclusion
This large population based health study has demon-
strated that in the period from mid 1980s to mid 2000s
BP in the population decreased considerably, especially
in the period from mid 1990s to mid 2000s, and even in
those who reported they had never taken BP medication.
The BP decrease was larger in elderly and might seem
paradoxically given the fact that body weight and the
prevalence of diabetes increased during the same period.
The BP decrease was, however, consistent with the
general improvement in the cardiovascular risk profile
and decreasing cardiovascular morbidity and mortality.
We have no reason to assume that the methods of blood
pressure measurement or selection bias can explain the
findings. The parallel decrease in heart rate might indi-
cate increased parasympathetic activity, like reduction in
the white-coat phenomenon, and a possible increased
use of beta blockers or calcium channel blockers for
other diagnosis than hypertension could have had some
effect. Additionally, salt consumption might have de-
creased. Finally, the data could support the “healthy
obese” hypothesis, i.e., that subgroups in the population
can sustain obesity without serious health consequences.
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